Jazz Pharmaceuticals plc

Listed Company

JAZZCIK 0001232524NasdaqLarge AcceleratedPharmaceutical PreparationsL2IEFY ends Dec 31

Period

FY 2025

Revenue

$4.27B

Net Income

—

Total Assets

—

Equity

—

Shares Out

62.74M

Op. Cash Flow

$1.36B

Business

Jazz Pharmaceuticals plc is a global biopharmaceutical company that discovers, develops and commercializes therapies in neuroscience and oncology focused on serious diseases with high unmet need. Its main products include oxybate therapies for sleep disorders (Xywav, Xyrem), cannabidiol for certain epilepsies (Epidiolex/Epidyolex), oncology agents (Zepzelca, Rylaze, Ziihera, Vyxeos, Defitelio) and related investigational candidates. The company operates integrated commercial, research and development, licensing and manufacturing activities across specialized therapeutic franchises. It commercializes products directly in the U.S., Europe, Canada and Australia and through specialty pharmacies, distributors, wholesalers, hospitals and global partners.

Summary from filing dated 2025-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	4,268	4,069	3,834	3,659	3,094
Cost of product sales (excluding amortization of acquired developed technologies)	503	446	436	541	441
Selling, general and administrative	1,809	1,385	1,343	1,417	1,452
Research and development	783	884	850	590	506
Intangible asset amortization	655	627	608	599	526
Acquired in-process research and development	948	10	19	444	0
Total operating expenses	4,698	3,352	3,256	3,725	2,924
Income (loss) from operations	−430	717	579	−66	170
Interest expense, net	−195	−238	−289	−288	−279
Foreign exchange gain (loss)	−3	−8	9	−19	−4
Income (loss) before income tax benefit and equity in loss of investees	−628	470	298	−373	−113
Income tax benefit	−272	−91	−120	−159	216
Equity in loss of investees	732,000	2	3	10	714,000
Net income (loss)	−356	560	415	−224	−330
Basic (in dollars per share)	−5.84	9.06	6.55	−3.58	−5.52
Diluted (in dollars per share)	−5.84	8.65	6.1	−3.58	−5.52
Weighted-average ordinary shares used in per share calculations - basic (in shares)	61	62	63	63	60
Weighted-average ordinary shares used in per share calculations - diluted (in shares)	61	66	72	63	60

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	1,392	2,413	1,506	881	591
Investments	1,050	580	120	0	0
Accounts receivable, net of allowances of $17,294 and $32,691 at December 31, 2025 and 2024, respectively	831	717	706	651	563
Inventories	417	480	597	714	1,073
Prepaid expenses	152	177	185	92	131
Other current assets	324	262	321	267	252
Total current assets	4,166	4,629	3,435	2,606	2,611
Property, plant and equipment, net	200	173	170	228	257
Operating lease assets	59	54	65	73	87
Intangible assets, net	4,430	4,756	5,418	5,794	7,152
Goodwill	1,829	1,716	1,753	1,693	1,828
Deferred tax assets, net	869	560	478	376	311
Deferred financing costs	8	9	6	9	12
Other non-current assets	99	114	67	55	41
Total assets	11,659	12,012	11,393	10,835	12,299
Accounts payable	122	78	103	91	100
Accrued liabilities	1,034	911	794	803	666
Current portion of long-term debt	1,030	31	605	31	31
Income taxes payable	56	19	35	8	10
Total current liabilities	2,243	1,039	1,537	933	809
Long-term debt, less current portion	4,328	6,078	5,108	5,693	6,019
Operating lease liabilities, less current portion	51	39	59	72	87
Deferred tax liabilities, net	594	677	848	944	1,301
Other non-current liabilities	125	87	105	107	117
Commitments and contingencies (Note 13)	—	—	—	—	—
Ordinary shares, nominal value $0.0001 per share; 300,000 shares authorized; 61,435 and 60,631 shares issued and outstanding at December 31, 2025 and 2024, respectively	6,000	6,000	6,000	6,000	6,000
Non-voting euro deferred shares, 0.01 par value per share; 4,000 shares authorized, issued and outstanding at both December 31, 2025 and 2024	55,000	55,000	55,000	55,000	55,000
Capital redemption reserve	473,000	473,000	473,000	472,000	472,000
Additional paid-in capital	4,240	3,914	3,700	3,477	3,535
Accumulated other comprehensive loss	−569	−948	−842	−1,126	−400
Retained earnings	646	1,127	879	734	830
Total shareholders equity	4,319	4,094	3,737	3,086	3,965
Total liabilities and shareholders equity	11,659	12,012	11,393	10,835	12,299

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Share-based compensation	291	248	227	222	189
Acquisition accounting inventory fair value step-up adjustment	148	135	151	273	223
Depreciation	42	33	30	30	27
Non-cash interest expense	33	22	22	38	93
Provision for losses on accounts receivable and inventory	19	28	11	15	20
Deferred tax benefit	−445	−208	−260	−292	69
Impairment of property, plant and equipment	0	0	61	0	0
Other non-cash transactions	3	18	11	−14	10
Accounts receivable	−106	−21	−52	−90	−93
Inventories	−86	−46	−13	−50	−49
Prepaid expenses and other assets	29	−22	−127	36	−83
Accounts payable	40	−20	10	−11	57
Accrued liabilities	77	86	−23	166	142
Income taxes payable	37	−15	25	−2	−16
Other liabilities	28	−39	−24	—	—
Net cash provided by operating activities	1,356	1,396	1,092	1,272	779
Acquisition of investments	−1,830	−1,305	−390	−61	−27
Asset acquisition, net of cash acquired	−858	0	0	—	—
Acquisition of intangible assets	−109	0	0	−25	−18
Purchases of property, plant and equipment	−59	−38	−24	−29	−28
Acquired in-process research and development	−43	−10	−19	−444	0
Proceeds from sale of an asset	28	0	0	—	—
Proceeds from maturity of investments	1,360	845	270	60	1,095
Net cash used in investing activities	−1,510	−508	−163	−446	−5,212
Repayments of long-term debt	−781	−31	−31	−582	−1,102
Share repurchases	−125	−311	−270	−54,000	0
Payment of employee withholding taxes related to share-based awards	−75	−58	−51	−45	−36
Proceeds from employee equity incentive and purchase plans	108	21	46	98	135
Repayment of 2024 Notes	0	−575	0	0	−219
Payment of debt modification costs	0	−6	0	0	—
Net proceeds from issuance of 2030 Notes	0	981	0	0	0
Net cash provided by (used in) financing activities	−873	21	−305	−529	3,971
Effect of exchange rates on cash and cash equivalents	7	−2	1	−6	−3
Net increase (decrease) in cash and cash equivalents	−1,021	907	625	290	−466
Cash paid for interest	249	315	333	271	138
Cash paid for income taxes, net of refunds	122	115	178	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro